Andrea Casazza
Head of Cancer Biology EPICS Therapeutics
Andrea Casazza is a cancer biologist with over 20 years of experience in oncology research and drug development. He currently serves as Head of Cancer Biology at EPICS Therapeutics, contributing to the development of a differentiated pipeline of RNA-based therapeutics and GPCR-targeted agents.
Andrea has a proven track record of translating scientific innovation into therapeutic programs. Prior to EPICS, he held senior roles within the Belgian biotech ecosystem, where he led cross-functional teams and advanced multiple drug discovery projects across oncology, neurodegeneration, and immunology. His contributions include the development of enzyme-activated prodrugs and immune-oncology agents, with expertise spanning target discovery, preclinical validation, and clinical trial design.
He holds a Ph.D. in Cell Science and Technology from the University of Torino and completed postdoctoral research at VIB Leuven. Andrea is an inventor on multiple patents and has authored over 20 publications in top-tier journals.
Seminars
- Positioning RNA epitranscriptomics as a novel small molecule modality for cancer therapy
- Exploring methyltransferase inhibition as a means to alter tumour cell phenotype and limit cancer adaptability
- Mechanisms underlying the pharmacology of METTL3 inhibition across tumor types
